A Phase 2/3 interventional study of topical application of oxygenated gel and topical application of Triamcinolone acetonide gel in Aphthus Ulcer, sponsored by British University In Egypt. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by British University In Egypt · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Ulcer with a site in Egypt — 3 open to participants now, 3 under way, 1 of them phase 3. Ulcer · Egypt.
Among the 22 studies in Ulcer with a site in Egypt, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 2/3, and was the 18th registered.
360 studies on the registry are indexed under Ulcer; 61 are open to participants now.
Browse Ulcer studies →3 of the 22 studies in Ulcer with a site in Egypt are open now. Recruiting first, the newest first:
Mansoura University · Sites in Egypt
Ages 18–80 · Healthy volunteers
Cairo University · Sites in Egypt
Ages 40–60
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 3 · Phase 4 1
First in 2012; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 65 across 292 interventional studies indexed under Ulcer.
Median enrollment 38 across the 20 interventional studies, 72 across the 2 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 22 have an industry lead sponsor. The 10 most frequent:
British University In Egypt is the lead sponsor of 70 studies on the registry; 22 are open to participants now.
British University In Egypt has 1 study filed under Ulcer — fewer than ten, so there is no comparison to draw.
2 of the studies in Ulcer with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06910579Phase 3British University In EgyptOxygenated Gel Therapy in the Management of Oral Aphthous Ulcers | 2027-01-30 |
| NCT07557524Cairo UniversityPulsed High Intensity Laser Versus Negative Pressure Therapy On Neuropathic Ulcers | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Ulcer with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Interventions of both groups:
Oxygenated gel Group: 15 patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days.
Triamcinolone acetonide Group: 15 patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.
Patients in both groups were reexamined after treatment at different intervals (day 3, day 5, day 7, and day 10).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.
Drug: topical application of Triamcinolone acetonide gel
15 patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days
Drug: topical application of oxygenated gel
patients who used oxygenated gel (Blue®m, Wijhe, Netherlands) were trained by the co-investigator (A.H) through real demonstration for topical application of the gel on aphthous ulcers, which entails the application of 1-2 ml of oxygenated gel directly to the ulcer two times per day and this was repeated for 7 days
patients were treated with Kenalog in orabase (Triamcinolone acetonide 0.1% oral paste 5g), four times (i.e., at 8 am, 12 noon, 4 pm, and 8 pm) a day for 7 days at intervention group.
Pain intensity
Visual Analog Scale (0-10), which measured a range of "no pain" to "unbearable pain" on a 100 mm horizontal line \[10\]. to determine the intensity of pain on day 0, day 3, day 5, day 7, and day 10
Time frame: 10 days
Size of ulcers (in mm)
after starting treatment, ulcer size was recorded on day 0, day 3, day 5, day 7, and day 10 using a calibrated dental probe with millimeter marking
Time frame: 10 days
Complete healing duration
the duration till complete healing is achieved is recorded in days
Time frame: 10 days
OHIP-14
has been assessed 1 week after intervention. OHIP-14 utilizes a scale with five categories (1 = never, 2 = hardly ever, 3 = occasionally, 4 = fairly often, and 5 = very often). A lower score in any of the five categories indicates higher satisfaction
Time frame: 10 days
Plan to share: Yes — all IPD that underlie results in a publication will be shared
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jan 2026 → Jan 2027 and completion Apr 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
British University In Egypt